L’association T-DXd et sotorasib a montré une efficacité prometteuse dans les études précliniques sur le cancer du poumon non à petites cellules porteur de la mutation KRAS G12C – Oncodaily
L’association T-DXd et sotorasib a montré une efficacité prometteuse lors d’études précliniques sur le cancer du poumon non à petites cellules porteur de la mutation KRAS G12C.
Contenu integral de l article
T-DXd Plus Sotorasib in KRAS G12C-Mutant NSCLC showed durable preclinical tumor regressions and highlighted HER2 testing gaps. , ADCs, Antibody drug conjugates, HER2, HER2 expression, HER2 IHC, KRAS G12C, KRAS G12C-mutant NSCLC, KRAS inhibitor resistance, Lung cancer, NSCLC, OncoDaily Lung, Precision Oncology, preclinical oncology, Sotorasib, T-Dxd, targeted therapy, Thoracic Oncology, Trastuzumab deruxtecan, xenograft models
Produkte zu diesem Artikel
Diese Produkte wurden automatisch anhand von Titel, Zusammenfassung und Inhalt zugeordnet.
Haeufig gestellte Fragen
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Sotorasib – Online kaufen SOTOLDX Sotorasib 120 mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.